Compare ARDX & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | LXRX |
|---|---|---|
| Founded | 2007 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 862.3M | 996.7M |
| IPO Year | 2014 | 2000 |
| Metric | ARDX | LXRX |
|---|---|---|
| Price | $3.24 | $1.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 6 |
| Target Price | ★ $12.90 | $4.55 |
| AVG Volume (30 Days) | ★ 4.1M | 2.9M |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.78 |
| EPS | N/A | ★ N/A |
| Revenue | $2,607,000.00 | ★ $49,803,000.00 |
| Revenue This Year | $19.98 | N/A |
| Revenue Next Year | $27.70 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 60.24 |
| 52 Week Low | $3.18 | $1.10 |
| 52 Week High | $8.40 | $2.68 |
| Indicator | ARDX | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 29.24 | 27.35 |
| Support Level | N/A | $1.50 |
| Resistance Level | $3.63 | $1.81 |
| Average True Range (ATR) | 0.11 | 0.11 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 12.50 | 1.79 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.